

# CONTINUOUS PROCESSING IN THE PHARMACEUTICAL INDUSTRY

## Changing the Mind Set

**K. PLUMB\***

*Integral Pharma Service, Sale, Cheshire, UK*

**T**he pharmaceutical industry is a highly regulated industry and all production must be carried out in accordance with good manufacturing practice. Traditionally, virtually all manufacturing operations have been carried out batch wise in spite of cost disadvantages and the fact that in many cases continuous processing could lead to the manufacture of purer products.

The regulatory environment tends to stifle any attempts to change the process once the development stage is over and the product and process have been licensed. This has created a mind set amongst the industry's professionals that batch processes are the only acceptable way forward. However; the regulatory authorities, particularly the Food and Drug Administration in America, have recognized that continuous processing has the potential to improve product quality and are encouraging the industry to reconsider their ideas. This paper examines how chemical engineers can use the opportunity that arises from this changed regulatory environment to revisit their own ideas and drive a change of mind set within the industry.

*Keywords: pharmaceutical industry; continuous processing; good manufacturing practice; barriers to change.*

### INTRODUCTION

The pharmaceutical industry is dominated by batch processes, so much so that naturally continuous process such as in-line milling and spray drying or semi-continuous processes like tablet compression are modified to make them into batch processes. This has arisen for historical reasons and is reinforced by the regulatory environment and the need to get new products to market as fast as possible. This is linked to a mind set that products can only be produced by batch processes if they are to comply with the regulatory quality requirements.

Ironically, batch processes have a number of problems, notably difficulties with scaling up and the difficulty in producing homogeneous processing conditions. This means that the products manufactured are often of a lower quality than need be the case. By-products lead to undesirable side effects and it is conceivable that in the past, products have been rejected at the clinical trials stage because they could not be made pure enough.

The regulatory and business environments are now changing. The pharmaceutical licensing authorities are recognizing that continuous processing can have a role to play and environmental, health and safety legislation is driving the industry towards more efficient processes. Also new products are becoming ever more expensive and time

consuming to discover, develop and launch onto the market and competition from generic manufacturers is become intense.

There now exists a window of opportunity for technical professionals within the industry to progress the appropriate use of continuous processing. The paper examines the background to this opportunity and the ways to progress changing the mind set of the professionals working in the industry.

### THE PHARMACEUTICAL MANUFACTURING PROCESS

#### The Ingredients

A pharmaceutical product contains two groups of materials, active ingredients and excipients. The active ingredients are those materials that have a therapeutic effect, whilst the excipients have no therapeutic effect but are necessary to ensure the final dosage form acts as intended. Typical excipients include water, lactose, starch, sugar and colouring but in practice there are a very large number of excipients in common usage.

#### The Manufacturing Stages

The pharmaceutical manufacturing can be broken down into a number of stages, see Figure 1. Frequently it is broken down into two major stages usually known as Primary and Secondary. These stages are commonly carried

\*Correspondence to: Mr K. Plumb, Integral Pharma Service, 38 Abington Road, Sale, Cheshire, UK.  
E-mail: keith@dpnadp-sale.demon.co.uk




Figure 1. Overview of the pharmaceutical manufacturing process.

out at different sites and can be carried out by a number of different manufacturers. The Primary stage consists of the manufacture of the active pharmaceutical ingredients (APIs), which can be made by either chemical synthesis or by biological processing followed by physical manipulation processes such as drying, purification and size reduction. In most cases the API, in bulk, is then shipped to a Secondary manufacturing site.

Strictly speaking the production of excipients is also a Primary stage but in general these products are manufactured by main stream producers who produce some of their products to the pharmaceutical specifications given in the various pharmacopoeias. The only major exception to this is sterile water, which is intended for products that are injected, this is treated in the same way as the active ingredients and it is usually produced on site by the pharmaceutical manufacturer.

The Secondary stage usually starts with the formulation of the final product in a bulk form, where one or more APIs are mixed with a number of excipients. These may undergo further physical manipulation such as drying, size reduction, size enlargement, filtration and sterilization. The bulk material is then turned into the final dosage form. In over 80% of the cases this is a tablet, but it could be capsules; a liquid in ampoules, vials, or bottles; creams in tubes or jars; aerosols in canisters or suppositories. Finally, the product is filled into its final packaging, such as bottles, blister packs or foil wraps that importantly includes the product information.

## QUALITY REGULATION

### Good Manufacturing Practice

The pharmaceutical industry is highly regulated with a number of regulatory systems. The technical requirements of Good Manufacturing Practice (GMP) are being harmonized but the regulations that oversee these are very different for the USA, the EU and Japan. However, all of these major markets require that products must be manufactured in line with GMP if they are to be allowed into the market place.

In the European Union the requirements for GMP are covered by Directive 2003/94/EC. Whereas in the United States the Federal Food, Drug and Cosmetic Act states that a pharmaceutical product may not be sold if it is adulterated. Section 501 (a)(2)(B) states that if a pharmaceutical product is not made to GMP it is by definition adulterated and cannot be sold.

GMP is defined by the EU Guide to Good Manufacturing Practice (European Regulations, Vol. 4, 2002) as follows:

Good Manufacturing Practice is that part of Quality Assurance which ensures that products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the Marketing Authorisation or product specification.

GMP must be applied to the manufacturing process after the 'critical step', which usually occurs when the final active molecule is being produced or an intermediate is being produced that has a major impact on the quality of the final product. This critical step usually occurs near the end of the API manufacturing process. Quality assurance measures also need to be in place for those parts of the process prior to the critical step. Since excipients do not include APIs they are not subject to the same level of scrutiny but quality assurance systems must be in place and the products must meet the specifications given in the appropriate pharmacopoeia.

The major thrust of GMP is to prevent the product becoming contaminated by particulates and micro-organisms (particularly from the human plant operatives) in the room environment, particulates generated by equipment, chemicals leached from the product contact parts and from other products being manufactured. It is the need to avoid contamination and cross contamination from other products that dominates the design of pharmaceutical manufacturing facilities and leads to the need for regular and extensive cleaning.

The guidelines to GMP, whilst not compulsory, form a detailed framework and working outside of them is only permissible if good scientific evidence for the alternative approach can be provided. The guidelines are fairly prescriptive, the EU guidelines include 18 annexes that include guidelines on the manufacture of various groups of products. The annex covering sterile products for example, indicates that sterile products shall be terminally sterilized using steam in an autoclave unless there is a scientific reason why this is not possible.

### Product and Manufacturing Licences

Before pharmaceutical products can be sold they must have a product licence from the relevant regulatory body, the Medicines and Healthcare products Regulatory Agency in the UK, the Food and Drug Administration in America, and so on. Also, the facility that is used to

manufacture the product must have a manufacturing licence. Both of these licences are time consuming and expensive to obtain.

The product licence includes information about how the product is manufactured and therefore once the licence has been obtained it is to be expected that any change to process will require more time and money to be spent on a revised product licence.

### Impact on Process Changes

It can be seen that the regulatory requirements to comply with GMP and the impact of including the method of manufacture in the product licence contribute to a mind set that is averse to moving outside the guidelines and/or changing the process after it has been licensed.

## SAFETY, HEALTH AND ENVIRONMENTAL (SHE) LEGISLATION

There is a perception that the licensing and GMP regulations are more important within the pharmaceutical industry than SHE legislation. However, a recent incident (pers. comm., 2004) illustrates the fallacy of this view. A relatively minor incident relating to the cleaning equipment on some key manufacturing equipment in a tablet facility was reported to the Health and Safety Executive as a result of the RIDDOR legislation within the UK. The resulting investigation nearly resulted in a Prohibition Order, if this had occurred the whole of the tablet facility would have shut down within a few days with the resultant loss of large amounts of money. This one safety issue could have stopped the production of a number of product ranges.

### ATEX Directive

The European Union ATEX directive has had significant impact on pharmaceutical manufacturing within the union. This is because it has codified the requirements for potential explosive atmospheres created by dust clouds. That is not to say that the industry has been ignoring the potential hazard but since there is now a legal requirement for manufacturers to classify the hazardous areas, equipment is being more rigorously specified and risk assessments have become more detailed. Also there is now a statutory requirement to reduce the potential risk by reducing the inventory of material within the manufacturing environment.

### Control of Substances Hazardous to Health (COSHH/OSHA)

As products become ever more potent, the requirement to comply with COSHH/OSHA regulations becomes more complex and expensive. Product containment making use of special devices such as split butterfly valves or various forms of barrier isolators is becoming common. However, these add significantly to the capital cost of the equipment [up to 50% more (Cliff, 2004)] and make the facility more complex to operate. Continuous processes allow the manufacturing equipment to be contained without resorting to this sort expensive measure and are likely to lead to significant capital cost savings.

### Integrated Pollution Prevention and Control (IPPC) and Other Environmental Legislation

The production processes for APIs tend to have low yields. This leads to the need to dispose of large quantities of waste. With multi-step complex processes there will be more waste product than saleable product even if the yield of each step is greater than 90%. The disposal of this material is becoming more expensive and more complex. There is an obvious advantage in increasing yields and reducing this problem.

## NEW PRODUCT DEVELOPMENT AND THE PHARMACEUTICAL MARKET PLACE

The driving force behind the pharmaceutical industry has been and remains the discovery of new molecular entities that can be patented. Once patented, licensed and launched on to the market there is the potential to make large profits. However, in general the cost of the research efforts is increasing whilst its efficiency is falling. The major pharmaceutical companies are finding it difficult to find new products at the rate necessary to continue with the expected profit growth. This means the issue of the cost of manufacturing products is starting to become more important. Following on from the recent mergers and acquisitions activities there is a drive to reduce costs by reducing the number of research, development and manufacturing facilities.

### Laboratory Scale versus Manufacturing Scale

New molecular entities are obviously developed at the laboratory scale. A large number of new molecules are produced by chemical synthesis or by biological fermentation processes, these are screened for pharmacological activity to find new products of potential commercial value. New molecules that appear to have potential have to be subjected to three stages of clinical trials. Each stage requires ever larger quantities of materials as the number of trials required increases at each stage. This means that in parallel with the clinical trials it is necessary to carry out scale-up trials to demonstrate that the molecule can be produced at a large enough scale to supply the third stage clinical trials. Much of this work is abortive because products frequently fail to move forward because they are not sufficiently efficacious or have too many side effects.

The scale required for Stage 3 clinical trials is usually large enough to produce sufficient quality for the initial launch of a product but if it is successful it is not very long before further scale-up is required to allow the required tonnage of material to be made.

### Speed to Market

The life of a patent is finite and varies around the world, in general more than half of the patent life of a new molecular entity is lost before the product can be launched. Once the patent protection has been lost it is possible for the original product developer to lose up to 90% of their market share, to generic manufacturers, within 12 months. With large numbers of products coming off patent there are plenty of companies who can make good profits from entering the market as soon as a patent expires. This is a developing market place.

One way to increase the speed with which a product can be brought to the market is to reduce the development time. If the scale-up step could be avoided it may be possible to gain months/years of additional time covered by the patent. Continuous processing via micro-reactors offers the possibility to avoid this scale-up phase as discussed before.

### Commercial Risk

The opportunity cost of failing to sell a successful pharmaceutical product can easily run into hundreds of millions of dollars. This means that pharmaceutical companies take a cautious approach to business risk. Using novel processes and untried manufacturing techniques will increase the business risk and so high level management will always err toward the tried and tested.

One area of risk that particularly affects the batch processing mind set is product recall. If a batch of material is found to be out of specification or contaminated and needs to be recalled this is inevitably expensive and it reflects badly on the manufacturer. The commercial risk is reduced if the batch size is kept small so that any recalls require the minimum amount of material to be returned and destroyed. The use of continuous processes will have to address this issue, if company managers are to accept the associated commercial risks.

### Product Pricing

The pharmaceutical market place falls into two major groups, the so called ethical products, prescription only patented products and generic products that have no patent protection. Generic products fall into two further categories, those that require a prescription and those that can be sold over the counter (OTC). The over the counter market differs in each country as the regulations covering the requirements for prescriptions are very different even across the EU. Antibiotics being OTC in Spain but prescription only in the UK, for example.

It would be expected that OTC products such as aspirin, paracetamol and ibuprofen would be under severe cost pressure, however this is not the case. A visit to any supermarket will show that branded versions of these products still command a price premium of four or five times over the unbranded products. This is surprising when you consider that in a highly regulated market it is unlikely that there will be any quality difference between the products. This seems to show the power of the 'reassuringly expensive' approach.

What is perhaps even more surprising is that whilst these products are made in large volumes there are no manufacturers using a continuous process. However, this is one area where continuous processing could be a serious possibility, there are the production volumes to make use of the commercial available equipment and so scale down (see below) should not be a problem. Also, competition from supermarket own brands is likely to begin to have sufficient impact on the product cost to provide the driving force for a change.

## THE NATURE OF BATCH PROCESS

Much of the resistance to change arises from the fear of the impact on product quality. However, batch processes

are not actually very good for product quality. Although the product leaving a batch reactor, crystalliser, dryer or whatever may be homogeneous the heat, mass and momentum transfer environment that the molecules and crystals within the batch have experienced during the process will be significantly different. During the process, temperature, velocity and concentration profiles will vary with position within the equipment and with time leading to processing inefficiencies. Most of the practices within the industry have been developed to overcome these deficiencies but this is poorly recognized and many of the practices are seen as a prerequisite to good quality management.

### Poor Understanding

Batch processes are poorly understood, time dependant and scale dependant operations. They are poorly understood at the micro-scale and have not until recently been studied in detail. In spite of this method of operation being used for thousands of years it still produces fluctuating and unpredictable results.

By comparison, most continuous processes are much simpler and far better understood. The mathematical tools to analyse these processes have been available for many years.

### Poor Yield

The varying heat, mass and momentum transfer in a batch reaction generally mean that yields are sub-optimal. If a 10 stage process has a yield of 50% at each stage then the overall yield will be  $0.5^{10} \times 100\%$  i.e., 0.097% raising the stage yield to 80% raises the overall yield to over 10% thereby giving more than a hundred times greater throughput in the same equipment.

Continuous processes for making the relevant chemicals have been reported in the literature that give significant improvements in yield over the batch process mainly because of improvements in temperature control and mass transfer.

### Intermediates

As a result of the low purity of materials made by batch processes and perhaps because of the approach taken by chemists at the laboratory scale, most APIs are isolated as a number of intermediates (usually solids). These arise as a result of the purification (often crystallization processes) that are required to isolate the desired chemical. Intermediates also allow the purity of the product to be checked at each stage and to identify problems before the final product is made. However, if reaction yields and conversions were improved and reactions were more predictable, less purification would be required. Also product quality could be monitored using on-line analysis.

A further major disadvantage of producing and analysing intermediates is cost of storing (working capital) and handling the solid intermediates (labour costs).

### Batch Processes Do Not Scale Up Well

Most pharmaceutical batch operations are carried out in agitated vessels, for liquids and slurries these will be the

classic stirred tank vessels. These processes are difficult to scale up and in general the regulatory authorities do not like processes to be scaled up by more than 10–1 at each stage of development. The scale-up problem can be illustrated by consideration of the blend time in a stirred vessel with baffles and a pitched blade turbine.

Nagata (1975) proposed that  $\theta \cdot N$  (where  $\theta$  is the blend time and  $N$  is the impeller speed), for a geometry similar system, is constant for a Reynold's number greater than  $10^4$ .

Also the power absorbed by an impeller is given by Oldshue (1985)  $P = N_p \rho N^3 D^5$  (where  $N_p$  is the power number of the impeller,  $\rho$  is the liquid density,  $N$  is the impeller speed and  $D$  is the impeller diameter) for a pitched blade turbine a typical value of  $N_p$  is 1.5.

Consider the scale-up of a process from 100 l to 10 000 l with a vessel  $L/T = 1$  and  $D/T = 0.33$ . Table 1 shows that scaling up to give a constant blend time requires impractical increase in power consumption. Using constant power per unit volume gives a more practical solution but the blend time will increase. Similarly scale-up using constant tip speed, also gives a practical power consumption but the blend time will increase nearly five times with a commensurate deterioration in yield and conversion resulting from a significant amount of time required to produce a reaction mass approaching homogeneity.

As a further problem the velocity profile within the vessel varies, there will be a high velocity close to the tip of the impeller and lowering velocity as the distance from the impeller increases. Numerous studies have shown that they are frequently complete dead spots within a stirred tank. These variations in velocity lead to variations in heat, momentum and mass transfer causing variations in temperature and concentration within the stirred mass. These variations lead to sub-optimal reaction profiles and a reductions in product quality. In summary a stirred vessel is not good at producing a high quality consistent product.

The discussion above has been based on stirred tanks containing liquids or slurries but the above points also apply to more solid based processes such as crystallization, filtration and drying.

Table 1. Batch agitation scale up

Parameter	Units	Lab	Pilot	Production	
Volume	V	l	100	1000	10 000
Vessel diameter	T	m	0.503	1.084	2.311
Height of liquid	L	m	0.503	1.084	2.311
Impeller diameter	D	m	0.168	0.361	0.771
Liquid density	$\rho$	kg/m <sup>3</sup>	1000	1000	1000
Liquid viscosity	$\mu$	Pa-s	0.001	0.001	0.001
Scale-up on constant blend time i.e., constant speed					
Speed	N	s <sup>-1</sup>	5.00	5.00	5.00
Renold's number	Re		137 807	639 643	2 968 962
Process power	P	kW	0.023	1.097	50.94
Scale-up on constant power per unit volume					
Speed	N	s <sup>-1</sup>	5.00	2.99	1.80
Renold's number	Re		137 807	383 462	1 066 985
Process power	P	kW	0.023	0.230	2.3
Scale-up on constant tip speed ND					
Speed	N	s <sup>-1</sup>	5.00	2.32	1.08
Renold's number	Re		137 807	296 896	639 645
Process power	P	kW	0.023	0.109	0.509

## Flexibility

One major advantage of batch processing equipment is flexibility. A set of stirred tank reactors, batch filters, centrifuges and dryers can, with persuasion, make virtually any chemical providing the materials of construction are suitable. Since the annual requirements for the APIs can often be very low, production facilities need to be as flexible as possible. Continuous processing will need to match this level of flexibility.

## CONTINUOUS PROCESSES

In contrast to batch processing, continuous processing is relatively well understood. At steady state, there are only three-dimensional problems instead of four dimensional problems because time is not relevant. Small scale continuous processes are easy to control and a constant temperature profile is easy to maintain.

## Number Up Instead of Scale Up

The Institution of Chemical Engineers 2004 Conference 'Switching from Batch to Continuous' had a number of papers demonstrating that various forms of micro-reactors can be used for chemical synthesis with very promising improvements in conversion and product quality. These reactors have the advantage that a large number of them can be used in parallel and so that basic scale is not altered. The production rate is increased by numbering up instead of scaling up.

A major advantage of this approach is that there is no need to carry out the scale-up development work in parallel with the clinical trials and scale-up to full manufacturing is achieved by having sufficient micro-reactors in parallel to achieve the require throughput.

At present this approach has a major problem. The micro-reactors so far developed are suitable for liquid but not for solids due to their very narrow pathways. Since most pharmaceutical active ingredients are large molecules they are also in general solids. This means that an




Figure 2. Typical product portfolio (Cliff, 2004).

alternative approach is required for crystallization, purification, drying, and other physical manipulation activities such as milling and granulation.

### Solid Processing and the Scale Down Problem

By the very nature of the pharmaceutical industry the product quantities are usually small. Figure 2 shows the product portfolio of a major pharmaceutical company. The biggest output is only 1200 t.p.a and most products are in the 100–1000 t.p.a. range. However, as products become even more potent the trend is for lower production rates in the range 10–100 t.p.a. Suitable equipment is available to manufacture most stages of the secondary production by continuous means, however most of this equipment is too large to be of use. For example, the Hosokawa Bepex laboratory scale Extrud-o-mat2 that can be used for continuous granulation produces 10–25 kg h. If this were operated continuous for 6000 h per annum it would produce 60 to 150 t.p.a., i.e., greater than the full production scale for many of the new potent products.

Laboratory development trials either require even smaller machines than those currently available or alternatively short product runs have to be carried out with the associated start up and shut down problems. This scale down problem needs to be addressed if progress is to be made in this area.

### Naturally Continuous Processes

Pharmaceutical processes often contain naturally continuous processes such as in-line milling and spray drying and semi-continuous processes such as tablet compression. However, the desire to maintain the batch approach and to form intermediates for analytical testing is so great, that these processes are started and stopped to make them batch processes. This start up and shut down is likely to form out of specification material so the whole 'batch' is charged to a blender to ensure the resulting batch is homogeneous. These naturally continuous processes are one of the obvious areas to start to change the mind set. Also, it will be easy to connect batch processes to these naturally continuous processes and run them semi-continuously and avoid the need to blend away the start up and shut down material.

### Process Analytical Technology

The Food and Drug Administration (FDA) in the USA has launched an initiative under the umbrella of Process Analytical Technology (Guidance for Industry, 2004). The initiative is promoting the use of in-line analytical technology as a way of improving the development, manufacture and quality assurance of pharmaceutical manufacturing. Interestingly the guidance document says that the initiative is: 'Facilitating continuous processing to improve efficiency and manage variability

- using small-scale equipment (to eliminate certain scale-up issues) and dedicated manufacturing facilities;
- improving energy and material use and increasing capacity'.

Process analytical technology has been successfully applied in a number of areas, laser diffraction for on-line

particle size analysis during in-line milling, near infra-red (NIR) technology for determining blend homogeneity and NIR technology for the on-line determination of moisture content. These successes have demonstrated the potential for these methods to be used to control continuous pharmaceutical processes in real time.

### Reduced Waste

One of the major advantages of continuous processing should be the reduction in the amount waste produced as a result of higher yield under better control. With environmental legislation become ever more restrictive and the cost of waste disposal rising rapidly, this is likely to be a major driver for the improvements to pharmaceutical processes.

### Reduced Energy

Batch processes are inefficient users of energy. They require large fixed utility generation equipment that is subject to large variations in load. A recent study by Thomas (2004) showed that by converting a batch process to a continuous process many of the utility and energy requirements could be cut to as much as 95%. One of the major areas of saving arises from the heating, ventilating and air conditioning savings arising from a much smaller facility. Similarly, an actual conversion (Thomas and Ramsay, 2004) from batch to continuous realized significant savings by eliminating the need for 16 000 tonnes of solvent and improving equipment efficiency from 30% to greater than 81%.

### Reduced Cost

With reduced waste and reduced energy, cost savings should accrue. Savings are also likely to occur in labour costs. The handling of batches of solids is nearly always labour intensive and close coupled continuous processes could overcome this problem.

Cost savings should also arise from smaller equipment (because of smaller utility needs as well as improved efficiency) but also from the space saved. Since secondary pharmaceutical manufacturing space costs in the order of \$3000 per m<sup>2</sup> there is a lot of potential for capital cost saving in this area.

## THE MIND SET

### The Current Mind Set

The current mind set is perhaps typified by following words from Guidance for Industry (2004):

Unfortunately the pharmaceutical industry has been hesitant to introduce innovative systems into the manufacturing sector for a number of reasons. One reason often cited is regulatory uncertainty, which may result from the perception that our existing regulatory system is rigid and unfavourable to the introduction of innovative systems. For example, many manufacturing procedures are treated as being frozen and many process changes are managed through regulatory submissions.

This is also true in the European Union, Lennart Ernerot (2004) suggests that the EU directives and GMP guidelines emphasize the need to consider batches and homogeneity.

The ideas and approaches of the regulatory bodies have permeated through the minds of all of the professionals within the pharmaceutical industry so that they are reluctant to move away from the tried and tested approach. It is not possible to blame any one group since they have all become used to this environment.

### Changing the Mind Set

There is now a window of opportunity to change the mind set of the professionals within the industry. The FDA have launched the Process Analytical Technology initiative that recognises that new approaches are required if product quality is to be improved. They have also recognized that continuous processing has a role to play.

The regulatory authorities have recognised that a time basis can be used instead of a batch basis for the release of finished products. They have also recognized the value of parametric release whereby a product is released by the Qualified Person on the basis that it has been manufactured in compliance with a number of parameters. Actual final analytical testing does not take place until after the material has been released.

Importantly the quality assurance professionals are starting to change their views, Michael Warmuth (2004), Corporation Divisional VP, Corporate Quality Operation, Abbott Laboratories, said:

Today the pharmaceutical industry focuses on R&D, with less emphasis on operations and maintenance and continuous improvement. Speed to market, no matter what production efficiency, was considered the key to success. But now the development of blockbuster drugs has slowed down the industry now needs to refocus its energies. The paradigm shift that the industry must make, to move forward, will be to gradually change from batch processes to continuous ones.

To make use of the window it will be necessary to have a strong group of people who will act as project champions and have the will to progress the necessary changes. In the author's opinion, Chemical Engineers are uniquely positioned to act as project champions because their education and experience provides them with the necessary tools and skills. Also, their drive will be enhanced by knowing that the reputation of the profession is likely to be greatly enhanced by helping to make the changes. However, success will depend on much more than just technical skills.

To ensure that all the relevant professionals are engaged in this exercise it will be necessary to focus on the following aspects.

- The potential to increase product quality thus helping to diffuse the concerns of quality assurance professionals and regulatory bodies. Also the potential to increase the benefit to the users of medicines in term of increased efficaciousness and reduced side effects.
- The technical solutions required to allow pharmaceutical products to be produced continuously.
- The benefits to pharmaceutical producers in terms of the speed to market for new products and/or in reduced production costs.
- The benefits to everyone resulting from improved occupational health, safety and environmental performance.

As well on focusing on these aspects it will be beneficial to keep the focus as tight as possible and initially attack the batch processing mindset in two distinct areas. Firstly, there is one area where continuous processing should be accepted more readily than other areas, this is the primary production of APIs by chemical synthesis. The second area is the secondary production of tablets, change will be more difficult in this area but since more than 80% of pharmaceutical products are sold as tablets, it is very important to change the mind set in this area.

#### *Example 1—API chemical synthesis*

APIs manufactured by chemical synthesis will benefit significantly from continuous production and implementation should be relatively straight forward particularly for those steps upstream of the critical step where GMP requirements are less onerous. This is because simpler to understand and control continuous processes should improve product quality, reduce SHE issues and reduce waste. Perhaps most importantly of all, allow the time to market to be reduced due the elimination of the need to scale-up the process.

The papers presented at the 2004 Conference 'Switching from Batch to Continuous' demonstrated that there is significant interest in this area. Research within universities has demonstrated that the required chemical reactions can be carried out in continuous reactors that can be numbered up to the required production scale. There are however, a number of stumbling blocks. Firstly, in order to move into secondary processing the products will need to be separated as solids and this area does not appear to have had much attention. Secondly, it is difficult to change existing processes to continuous processes because of the embodiment of the process in manufacturing licences.

The author is in no doubt that the focus will move to the solid separation problem once continuous processes are developed for new products. It is the speed to market factor that is most likely to drive this change and once a continuous route is chosen it will be locked in by the manufacturing licence. Also, if it can be demonstrated that an API produced continuously is purer than one produced by a batch process then the regulatory authorities will be pushing for as many new APIs to be manufactured continuously as is possible.

Moving from batch to continuous processing in this area is currently being championed by a number of organization including the Institution of Chemical Engineers and the Crystal Faraday Partnership. Their annual conferences are providing a show case for the new technology and creating significant interest.

In summary, the change of mind set needs to take place in the development departs of the pharmaceutical manufacturers where there is the opportunity to introduce continuous process for new products, thereby allowing this technology to permeate into the API manufacturing industry and overcoming the difficulty of the manufacturing process being embodied in the manufacturing licence.

#### *Example 2—Tablet manufacture*

Although the manufacturer of tablets is heavily focused on solids and materials handling, Chemical Engineers have built up a significant amount of expertise in this technology and can also act as champions in this area. The

author has already taken a lead in this area by setting a working group under the auspices of the Institution of Chemical Engineers Pharma Subject Group (PSG). This working group includes a wide cross section of engineers and the scientists from the pharmaceutical industry. The objectives of this group are:

- To make use of the naturally continuous processes to overcome the conservatism of the industry by adapting the stages of the manufacturing process so that continuous concepts can be developed with well known and trusted processes, thereby minimizing commercial risk.
- To examine the product quality benefits that can arise from using continuous process and how the use of 'Process Analytical Technology' will be simpler with continuous processes. Also to quantify the impact of the poor control resulting batch processing on product quality.
- To set up a precompetitive demonstrator project with the intention of demonstrating the practicality and flexibility of producing pharmaceutical products in tablet form using a continuous process.
- To investigate the scale down problem with particular emphasis on allowing production lines to be dedicated and thereby reduce the need for extensive down time for between-product cleaning.
- To fully quantify the benefits of continuous processing in terms of safety, occupational health, environmental, issues in particular, COSHH, ATEX and IPPC; including the impact of reduced inventories resulting for compact continuous processes.
- To fully quantify the achievable reduction in product cost.
- To investigate the impact of continuous processing on the whole supply chain where there is opportunities for significant simplification and cost saving.
- To develop sources of funding that will allow the technology to be moved forward independent of immediate commercial requirements.

It is the general view of those involved that the technical issues will be easier to overcome than the softer issues of the natural conservatism of a highly regulated industry. However, in spite of the attraction of making the full jump to a continuous process, taking small steps forward is likely to be more effective in overcoming conservatism and reducing commercial risk.

An example of this kind of step forward would be the use of the naturally continuous processes of milling wet granulate before drying and milling the dry granulate and replacing the batch drying with continuous drying. These three stages are at the heart of the traditional granulation process and the batch drying is very energy and space intensive and significant benefits could be achieved by just changing the drying process. If the rest of the process remains unaltered confidence can be built up in continuous processing and further continuous steps added over time.

#### What are the Chances of Success?

A number of companies and groups of professionals have tried to make this move in the past. In view of the poor performance of batch process illustrated above, it would have been expected that this move would have been easy to make. However, the conservatism of the regulators and

the industry has fixed batch processing into the mind set and attempts to move to continuous processes have not been a success.

However, recent changes have increase the likelihood of success.

- The regulatory authorities, particularly the FDA have begun to realise that batch processes are not as easy to bring under control as continuous process.
- Research projects are demonstrating that many of the required chemicals can be made to a higher purity with continuous processes than batch processes.
- The pressure to bring new products to market is significantly greater than it used to be.
- The cost of manufacture is becoming more important as established products reach the end of their patent life.
- The pharmaceutical industry is coming under increasing pressure to improve their safety, occupational health and environmental performance.
- Chemical engineers have become more and more involved in the pharmaceutical industry over time and they have now realised that they are in a lead position to drive forward the technologies to make this change.

In the discussions that the author has had with other technical professionals there has been a strong recognitions the softer people orientate issues will be more difficult to overcome than the technical issues. This acceptance is causing the group set up by the PSG to look at ways of meeting the challenge of the people issues.

With technical professions spending time thinking about how to get their ideas generally accepted and bearing in mind these significant changes listed above, along with amount interest that has been shown and the progress that has been to made to date; the chance of success appear to be high.

We should also remember that there are significant benefits to moving to continuous processes. The benefits will affect all parts of the industry and have an impact on the speed to market, product quality, facility capital cost and product cost as well as leading to a marked improvement in safety, occupational health and environmental factors. These benefits will be more marked now than they would in the past because the climate of the pharmaceutical industry has made all of them significantly more important. Such as the strengths of these benefits that they should far outweigh the negative effects of conservatism and concerns about the commercial risk. As Michael Warmuth (2004) said, without the blockbusters to carry the industry forward a paradigm shift is required to embrace the benefits of continuous processing.

#### THE CHEMICAL ENGINEER'S CHALLENGE

As a profession, Chemical Engineers must now ensure that they are involved with pharmaceutical product development in the laboratory, so that they can use their skills to ensure that the most efficient process is used to manufacture pharmaceutical products. If they work together with the other professionals in the industry they have the opportunity to bring about the level of change that came about within the oil and gas industry during the 1950s and 1960s. Since the health mankind and the industry's impact on the natural environment of the world will be to a great extent dependent



of their efforts to improve efficiency, I believe that the Chemical Engineers working within the pharmaceutical industry are duty bound to set about changing their own mind set and helping to change that of others.

If this opportunity is missed, it is unlikely that the profession will have another opportunity to have such an impact on the industry and the initiative will pass to a different group of professionals. It is unlikely than any other group will have the required skill to reap all of the benefits to mankind that Chemical Engineers can and we will all be the poorer for their failure.

### REFERENCES

- Cliff, M., Future Oral Solid Dose Manufacturing Technology—Continuous Granulation? ISPE UK Annual Meeting, Newcastle Upon Tyne, 11 November 2004.
- Ernerot, L., Is continuous production and real time release compatible with current legislation? What needs to be changed? ISPE UK Annual Meeting, Newcastle Upon Tyne, 11 November 2004.
- European Regulations, Vol. 4, 2002, *Guide to Good Manufacturing Practice*.
- Guidance for Industry PAT—A Framework for Innovative Pharmaceutical Development, Manufacturing and Quality Assurance, September 2004.
- Nagata, S., 1975, *Mixing: Principles and Applications* (Wiley, New York, USA).
- Oldshue, J.Y., 1983, *Fluid Mixing Technology* (McGraw-Hill, New York, USA).
- Personal communication, 2004.
- Thomas, H., *The Reality of Small Scale Continuous Processes*, IChemE, Switching from Batch to Continuous Processing conference, London, 22–23 November, 2004.
- Thomas, P.W. and Ramsay, A., *Continuous Processing Chemistry in Commercial Practice*, IChemE, Switching from Batch to Continuous Processing conference, London, 22–23 November 2004.
- Warmuth, M., Interphex Conference, New York, March 2004.

*This paper was presented at the 7th World Congress of Chemical Engineering held in Glasgow, UK, 10–14 July 2005. The manuscript was received 15 December 2005 and accepted for publication 22 March 2005.*